JENKEM(SH:688356)2026-01-22 10:00Revenue Projections - The company expects to achieve an annual revenue of approximately CNY 315 million in 2025, an increase of CNY 87.90 million or 38.71% compared to the previous year[4]. - The previous year's revenue was CNY 227.10 million, with a net profit of CNY 29.84 million attributable to the parent company[8]. Profit Projections - The projected net profit attributable to the parent company for 2025 is estimated to be between CNY 60 million and CNY 66 million, representing an increase of CNY 30.16 million to CNY 36.16 million, or a growth of 101.09% to 121.20% year-on-year[5]. - The net profit attributable to the parent company after deducting non-recurring gains and losses is expected to be between CNY 45 million and CNY 50 million, an increase of CNY 25.52 million to CNY 30.52 million, or a rise of 131.01% to 156.68% year-on-year[5]. Factors Influencing Performance - The significant growth in revenue and profit is primarily attributed to increased order income from the launch of new products by overseas pharmaceutical clients[10]. Audit and Disclosure - The company emphasizes that the performance forecast has not been audited by a registered accountant and is based on preliminary calculations by its financial department[7]. - Investors are advised to note that the forecast data is preliminary and the final audited financial data will be disclosed in the official 2025 annual report[12].